



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/563,024	12/30/2005	Dan Akerfeldt	030481-0251	3920
22428	7590	06/25/2009		
FOLEY AND LARDNER LLP			EXAMINER	
SUITE 500			BLATT, ERIC D	
3000 K STREET NW				
WASHINGTON, DC 20007			ART UNIT	PAPER NUMBER
			3734	
			MAIL DATE	DELIVERY MODE
			06/25/2009	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/563,024	<b>Applicant(s)</b> AKERFELDT ET AL.
	<b>Examiner</b> Eric Blatt	<b>Art Unit</b> 3734

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED. (35 U.S.C. § 133).

Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on 13 April 2009.  
 2a) This action is FINAL.      2b) This action is non-final.  
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 1-5,8,9 and 11-23 is/are pending in the application.  
 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.  
 5) Claim(s) \_\_\_\_\_ is/are allowed.  
 6) Claim(s) 1-5,8,9 and 11-23 is/are rejected.  
 7) Claim(s) \_\_\_\_\_ is/are objected to.  
 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.  
 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) Notice of References Cited (PTO-892)  
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  
 3) Information Disclosure Statement(s) (PTO-166/08)  
 Paper No(s)/Mail Date \_\_\_\_\_

4) Interview Summary (PTO-413)  
 Paper No(s)/Mail Date \_\_\_\_\_

5) Notice of Informal Patent Application  
 6) Other: \_\_\_\_\_

**DETAILED ACTION**

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 16 March 2009 has been entered.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-4, 8, and 11-23 are rejected under 35 U.S.C. 103(a) as being unpatentable over Akerfeldt et al. (WO 00/78226) in view of Torgerson et al. (US 6,361,551) and Grafton et al. (US 2003/0050667).

Akerfeldt discloses a method and device (Figures 1-2) for sealing a puncture in a vessel, comprising a sealing element 2 configured to be placed against a wall of the vessel and to seal the puncture in the vessel by contacting the vessel wall, an outer member 3 configured to be placed outside of the vessel. Akerfeldt additionally discloses an elongated member comprising at least suture 6 and longitudinally

extending past 7. The elongated member 6, 7 is configured to extend in an incision canal leading to the puncture in the vessel and hold together the sealing element and the outer member. Outer member 3 comprises a locking element 3 connected to the elongated member and adapted to be positioned against an outer surface of the vessel wall, and the sealing element is in the form of a plug. The inner member 2 comprises an anchor member 2 connected to the elongated member 6, 7. The outer member 3 comprises a second sealing element 3 having saw-teeth that fit into corresponding recesses on a portion of the elongated member 6, 7 that extends through the second sealing element 3.

Akerfeldt fails to teach that the elongated member comprises threads not having haemostatic material surrounding a haemostatic core (Claim 1), the elongated member is coated with the haemostatic material (Claim 11), the elongated member is impregnated or soaked with the haemostatic material (Claim 12), or the elongated member is a multifilament comprising several filaments, each of which is coated with the haemostatic material (Claim 13). Akerfeldt additionally does not disclose that the haemostatic material is collagen.

Torgerson discloses a fiber (elongated member) wherein the elongated member comprises a haemostatic material (Columns 1-3), the elongated member is coated with the haemostatic material (Columns 1-3), the elongated member is impregnated or soaked with the haemostatic material (Columns 1-3), and the elongated member is a multifilament comprising several filaments, each of which is coated with the haemostatic material (Columns 1-3, Column 13, Lines 14-15). Additionally, Torgerson discloses that

said haemostatic material is collagen. The fiber taught by Torgerson is entirely haemostatic and lacks the claimed threads that do not have haemostatic material surrounding the fiber. Grafton teaches increasing the strength of a suture by providing a high strength cover comprising braided polyethylene fibers over a core comprising a second material. This configuration allows the suture to have the beneficial properties of the second material while increasing its tensile strength. It would have been obvious to one of ordinary skill in the art at the time of the invention to provide a braided polyethylene fiber cover over the fiber of Torgerson as taught by Grafton in order to provide a high strength fiber with improved haemostatic properties. Further, it would have been obvious to one of ordinary skill in the art at the time of the invention to modify the apparatus of Akerfeldt by substituting the modified elongate member taught by Torgerson and Grafton for the elongated member 10 for purposes such as encouraging blood to coagulate, thereby preventing the vessel wall from leaking.

Akerfeldt does not disclose that the elongated member having a diameter that is small, less than 25%, preferably less than 10%, in comparison to the diameter of the sealing element. It would have been obvious to one of ordinary skill in the art at the time of the invention to modify the dimensions of the elongated member and the sealing element since it has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. *In re Aller*, 105 USPQ 233.

Claims 5 and 9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Akerfeldt et al. (WO 00/78226) in view of Torgerson et al. (US 6,361,551) and Grafton et al. (US 2003/0050667) as applied to claims 4 and 8 above, and further in view of Kensey et al. (US 5, 531,759).

Akerfeldt, Togerson and Grafton teach all elements of claims 5 and 9 as previously discussed except for the elongated member, plug, and locking element/second sealing element comprising a haemostatic material. Kensey discloses a related closure device and teaches that it was known to provide a haemostatic agent blended into or coated upon the elongated member, the plug, the locking element, or any combination thereof. (Column 9, Lines 13-18) It would have been obvious to one of ordinary skill in the art at the time of the invention to modify the apparatus of Akerfeldt by having the elongated member, the plug, and the locking element comprise a haemostatic material for purposes such as encouraging blood to coagulate, thereby preventing the vessel from leaking. So modified, said elements are configured to introduce haemostatic material into the incision canal to reduce secondary bleeding into the incision canal.

#### ***Response to Arguments***

Applicant's arguments with respect to claims 1-5, 8, 9 and 11-23 have been considered but are moot in view of the new ground(s) of rejection.

#### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Eric Blatt whose telephone number is (571)272-9735. The examiner can normally be reached on Monday-Friday, 9:00 AM-6:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Todd Manahan can be reached on 571-272-4713. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Eric Blatt/  
Examiner, Art Unit 3734

/Todd E Manahan/  
Supervisory Patent Examiner, Art Unit 3734